Cue Biopharma, Inc. (CUE) CEO Dan Passeri on Q3 2018 Results - Earnings Call Transcript [Seeking Alpha]
Cue Biopharma, Inc. (CUE)
US:NASDAQ Investor Relations:
cuebiopharma.gcs-web.com/news-releases
Company Research
Source: Seeking Alpha
Cue Biopharma, Inc. (NASDAQ: CUE ) Q3 2018 Earnings Conference Call November 20, 2018 4:30 PM ET Executives John Woolford - Westwicke Partners Dan Passeri - President and CEO Anish Suri - Chief Scientific Officer Bethany Mancilla - Chief Business Officer Kerri-Ann Millar - VP of Finance and Principal Accounting and Finance Officer Analysts Mark Breidenbach - Oppenheimer & Co. Gil Blum - Needham & Company Yale Jen - Laidlaw & Company Lou Basenese - Disruptive Tech Research Operator Good afternoon, and welcome to Cue Biopharma's Quarterly Investor and Analyst Update Conference Call. All lines have been placed on mute to prevent any background noise. Following the speaker's prepared remarks, there will be a question-and-answer session. As a reminder, this call is being recorded. I will now turn the call over to the company. John Woolford Good afternoon. This is John Woolford from Westwicke Partners. Thank you for joining us on today's investor an
Show less
Read more
Impact Snapshot
Event Time:
CUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CUE alerts
High impacting Cue Biopharma, Inc. news events
Weekly update
A roundup of the hottest topics
CUE
News
- Cue Biopharma, Inc. (NASDAQ: CUE) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $6.00 price target on the stock.MarketBeat
- Cue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium [Yahoo! Finance]Yahoo! Finance
- Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers SymposiumGlobeNewswire
- Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference [Yahoo! Finance]Yahoo! Finance
- Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceGlobeNewswire
CUE
Earnings
- 8/8/23 - Beat
CUE
Sec Filings
- 3/11/24 - Form SC
- 3/8/24 - Form 4
- 3/8/24 - Form 4
- CUE's page on the SEC website